Most deeptech startups wait too long before engaging with industry.

They focus on improving the technology, generating more data, preparing for fundraising.

But without early commercial traction fundraising becomes harder, credibility remains limited, strategic direction stays unclear.

The result: years of effort with no external validation.

I work with founders to transform their technology into a clear, credible, and sellable opportunity, and help them engage the right industrial partners early.

Not as a consultant, but as a sparring CEO.

A focused engagement to move from “promising technology” to real partnership opportunity.

Scope

• Clarify what can be sold today (not in 3 years)
• Define a compelling and realistic use case
• Identify the right strategic partners
• Build a clear, credible narrative
• Structure an efficient outreach approach
• Support ongoing discussions

Outcome

• A concrete partnership strategy
• Qualified discussions with relevant partners
• A significantly higher probability of securing a first deal

Deeptech / biotech startups (1–4 years)

Already funded (pre-seed to seed or beyond)

Strong technology, but no industrial deal yet

Founders under pressure to demonstrate traction

As the CEO and co-founder of a biotech startup, I secured a partnership with a Nasdaq-listed company at an early stage, long before full validation.

I know how difficult this phase is, and what it takes to get a first and early deal done.

PhD Consulting was founded by Pierre Bauër.

I combine a PhD in physics, an MBA, and hands-on experience across startups, industry, and research. I have led deeptech and biotech projects from zero to strategic partnerships and first sale, raised funding, and worked closely with both scientific and business stakeholders.

I now work with a small number of companies where I believe I can create decisive impact.